Renal Injury During Long-Term Oral Antiviral Therapy in Chronic Hepatitis B (CHB)
YaYunLiu1, WeiLiao1, QianHe2, AiJingXu1, JianYaXue1, ChengZhongLi1, XueSongLiang1*
1Department of Infectious Diseases,ChanghaiHospitalof Navy
Military Medical University, Shanghai, China
2Department of Health Statistics, Navy Military Medical University, Shanghai, China
*Corresponding author:Xue Song Liang, Associate Professor, Department of Infectious Diseases, Changhai Hospital of Navy Military Medical University, Shanghai, China. Tel: +8602131161902; Email:liangxuesong2000@163.com
Received
Date: 25 November, 2017;Accepted Date:10 January, 2018;Published
Date:17 January, 2018
Citation:Liu YY, Liao W, He Q, Xu AJ, XueJY,et al. (2018) Renal Injury During Long-Term Oral Antiviral Therapy in Chronic Hepatitis B (CHB). J Dig Dis Hepatol: JDDH-139. DOI: 10.29011/2574-3511. 000039
1. Summary
1.1. Aim: To determine the incidence and clinical outcome of long-term nucleot(s)ide analogues (NAs) usage related renal injury in patients with chronic hepatitis B (CHB).
1.2. Methods: A real-time prospective observation study was carried out between March 2014 and May 2017. 255 patients with CHB,which have been receiving one or two types NAs for antiviral therapy for more than six months, were enrolled. Serum and urinary β2microglobulin (β2 MG), serum phosphorus and calcium level, serum creatinine (Scr) and estimated glomerular filtration rate (eGFR) were determined for all patients at the enrollment and every 6 months during follow-up. Patients were followed up for 52 weeks.
1.3. Results: At the enrollment 27(10.58%)NAs long-term treated CHB patients showed mild or moderate eGFR value decrease, but the mean change of eGFR value among different therapy groups had no significant difference (p=0.925). But at the enrollment 135 (52.55%) NAs long-term treated CHB patients showed serum or urinaryβ2 MG level abnormality. Among different NAs groups the abnormal rate of urinary β2 MG level of ADV group was the highest and was significantly higher than that of LDT group [69.88% Vs14.81%, p=0.002].Multivariate analysis found that ADV (OR = 1.07, 95% CI=0.38-3.04, p=0.0016) and LDT (OR=0.10, 95% CI=0.03-0.40, p=0.0011) were both independent factors for urinary-β2 MG abnormality rate. Age (OR=1.02, 95% CI=1.00-1.05, p=0.00478) was also the independent risk factors for urinary β2 MG abnormality rate. For eGFR level change, age was the only independent risk factor (t=4.48, p<0.0001) and LDT was the unique drug which related to eGFR change (t=2.33, p=0.0204). At the end of 52-weeks’ follow-up urinary β2MG level of patients in ADV-excluding therapy group decreased at an average of 3.94mg/L, and eGFR level increased at an average of 1.7 ml/minute. But for patients in ADV-including group, urinary β2MG level increased at an average of 1.41 mg/L and eGFR level decreased at an average of 5.66 ml/min.Furthermore, at the end of 52-weeks’ follow-up the urinaryβ2MG level in only 7(11.36%) patients recovered completely.
1.4. Conclusion: During long-term NAs anti-HBV therapy, CHB patients developed mainly proximal tubular damage. For monitoring NAs related subclinical renal injury low-molecular-weight protein markers such as urinary β2MG was more sensitive than eGFR level. Prolonged NAs especially ADV antiviral therapy may be accompanied with irreversible renal damage even renal failure.
2.
Keywords:Antiviral
Therapy;ChronicHepatitis B (CHB);EstimatedGlomerular Filtration Rate (eGFR);Hepatitis
B Virus (HBV);Immunohistochemical;Nucleoside/Nucleotide Analogue (NAs); Renal Tubular;Serum
creatinine (Scr);Urinary β2microglobulin (β2 MG)
1. Introduction
Chronic Hepatitis B Virus (HBV) infection
is one of the main causes of chronic liver injury. Around the world about 2
billion people has been infected, and more than 3500 million people were
chronic HBV carriers [1,2]. Development of anti-HBV Nucleoside/Nucleotide
Analogues(NAs) in the last twenty years have changed the history of Chronic
Hepatitis B(CHB) treatment [3,4]. To now five NAs have been approved for CHB
antiviral therapy including lamivudine (LAM), adefovir dipivoxil(ADV),
telbivudine(LDT), entecavir(ETV) and tenofovir (TDF).
Though NAs can validly inhibit HBV replication and postpone disease progression, these NAs could not eliminate HBV replication template covalently closed circular DNA (cccDNA) and HBsAg clearance is also very rare. As a result, the majority of CHB patients will have to receive long-term or even lifelong NAs treatment to achieve disease remission or serologic endpoints, especially patients with advanced liver disease and cirrhosis[5-6]. As NAs’ wide application, safety data of NAs were of paramount importance in clinical practice. Generally, the security of these NAs is good during registration trials[8-13],but there have been reports of serious adverse events including myopathy, neuropathy, pancreatitis and renal impairment during post marketing surveillance[14-18].
Nephrotoxicity may occur in a small, yet significant, proportion of patients receiving nucleotide analogs. In ADV 5 years registration study, 3%-4% patients developed Serum creatinine (Scr) elevation at average of ≥0.5mg/dL every year and that of controls was 0%[19]. In TDF 5 years registration study, 1% patients also developed similar renal toxicity [20]. Along prolonged ADV application in clinical practice, more and more nephrotoxicity had been reported, including Fanconi syndrome [21-23].
Registration reports of these NAs suggested that the renal injury was largely reversible with dose adjustment or cessation of therapy. But post marketing surveillance found that renal tubular dysfunction is partially reversible with changing to other antivirals in patients received prolonged ADV therapy [24]. In order to evaluate the incidence and outcome of long-term NAs usage related renal tubular dysfunction, 255 CHB patients having been receiving NAs for anti-HBV for more than 6 months were enrolled. Urinary and serum β2microglobulin (β2-MG), serum calcium, serum phosphorus and Scr were monitored. Estimated glomerular filtration rate (eGFR) was calculated by using the CKD-EPI equation [25]. Then patients who developed renal injury during antiviral therapy were intervened and followed up prospectively.
2. Methods
2.1. Patients
The observational study was carried out on all patients with CHB who were admitted to the outpatient of the Department of Infectious Diseases of Shanghai Changhai hospital. The study was done during the 3-years period from March 2014 to May 2017.
2.2. Patient Management and Follow-Up
All
patients were subjected to complete history taking by a specialist from the
liver diseases center including general social data, antiviral therapy history,
viral data, biochemical data, manifestations and renal function data at the
start of antiviral treatment. The major inclusion criteria included HBV
mono-infection and having been receiving NAs antiviral therapy for more than 6
months at screening.Exclusion criteria included combining with diabetes,
chronic renal insufficiency, rheumatic disease, hypertension and other
cardiovascular diseases which may cause renal injury.The subjects assigned as
disease controls were patients with CHB and first-time disease
flare, and all of them did not receive antiviral therapy 6 months before
screening and were matched to study groups by age, sex, and clinical diagnosis.
2.3. Laboratory Tests
Qualitative tests for albuminuria and levels of urine β2 MG, urine micro-protein, Serum creatinine (Scr), serum calcium, serum phosphorus, HBV DNA load, and alanine aminotransferase (ALT) were conducted. Quantitative analyses of HBsAg, HBeAg, and HBeAb were also performed. Using the data for Scr levels, we calculated the eGFR by using the CKD–EPI equation.
Renal function data at the start of antiviral treatment was determined as the most recent creatinine measurement before antiviral treatment, if available, or the first value obtained on the first three month of antiviral therapy.
2.4. Treatment Adjustment and Follow-Up
All patients with one or more abnormal renal function indicators at the enrollment were given antiviral strategy adjustment according to the Guidelines for Treatment of Chronic Hepatitis B [26,27] and were followed up for another 52 weeks. In brief, the patients without history of drug-resistant mutation were shifted to other non-cross-resistant antivirals, whereas those with drug-resistant mutations were shifted to ETV 1.0 mg/day or ADV plus LDT.
2.5. Ethical Aspects
This study was in compliance with Helsinki Declaration and was approved by the Medical Ethics Committee of Shanghai Changhai Hospital. All the enrolled patients gave their written informed consent.
2.6. Statistical Methods
All data were analyzed with SAS9.4 (SAS Institute Inc., USA). A two-sided p-value < 0.05 was considered as statistically significant. Categorical variables were expressed as number (%), and continuous variables were expressed as mean ± standard deviation (±SD) or median (Q1-Q3). Categorical variables were processed usingx2 test. Continuous variables were compared using one-way Kruskal-Wallis or ANOVA analysis in accordance with the normal test result. The logistic regression model or general linear model analysis was used to estimate the risk factors of categorical variables or continuous various respectively.
3. Results
3.1. Demographic and Clinical Data Among Patients with Chronic Hepatitis B
In
this study 380 patients with CHB and having been receiving NAs antiviral
therapy for more than 6 months were screened. 125 of them were ruled out for
being accompanied with hypertension, diabetes, chronic kidney disease or
history of liver cancer respectively. At last 255 patients were included in
this study. 176 patients were receiving different NAs mono-therapy respectively
(ADV, 83 patients; ETV, 39 patients; LAM, 27 patients and LDT, 27 patients) and
the other 79 patients were receiving LAM or LDT or ETV plus ADV antiviral
therapy at the enrollment. 46/79 of those patients who were
receiving NAs combined therapy had drug- resistant mutation history during the
long-term antiviral therapy. A total of 25 patients with CHB and first-time
disease flare and matched with the treatment groups by age, sex, and clinical
diagnosis but did not receive any antiviral therapy prior to the study were
included as disease controls.
As
shown in Table 1, patients in different treatment groups had good comparability
in the gender proportion, liver hardness and Scr level or eGFR value before
antiviral treatment. All the treatment groups showed good comparability in age
and gender with the disease controls. Patients
in LDT therapy group were significantly younger than those in LAM or ADV
therapy group (P=0.06, 0.03). Therapy duration of these patients varied from 6
months to 132 months. The median therapy duration of ADV, or LAM or NAs
combined therapy group was longer than that of LDT or ETV mono therapy group
(all P value <0.05). All patients in therapy groups obtained good viral
inhibition and ALT recovery when been enrolled in this study.
3.2. Renal Function Characteristics of Patients with CHB and Being Receiving Long-Term NAs Therapy
To correct a deviation of age and treatment duration among different therapy groups, general linear model or logistic regression model analysis was used. As showed in Table2, adjusting influence of age and treatment duration, the mean change of eGFR value after long-term NAs antiviral therapy among different therapy groups had no obvious difference(p=0.925). But there were significant difference of serum β2 MG and urinary β2 MG abnormal rate among different therapy groups (p<0.0001 Vs p=0.002). Further comparison between any two groups found that there were higher urine β2MG abnormal rate in ADV therapy group than that in LDT therapy group (p=0.032), but there was no significant difference between ADV group and any other therapy groups [LAM(p=0.179), ETV(p=0.203) and NAs combine therapy(p=0.221)]. Unlike urine β2MG, serum β2MG mean level in ADV group was higher than both that in LAM therapy group (p=0.041) and ETV group (p=0.007), but there was no significant difference between ADV and LDT therapy group (p=0.45).
3.3. Relative Risks of Renal Injury During Long-Term NAs Antiviral Therapy in Patients with CHB
Renal
injury risk factors for patients with CHB during long-term NAs anti-HBV therapy
were analyzed by using general linear model or logistic regression model. The
influence factors assessed including age, antiviral strategy and treatment
duration.We found that both ADV (OR=1.07,95%CI=0.38-3.04,p=0.0016) and LDT (OR=
0.10,95%CI=0.03-0.40,p=0.0011) therapy were related to urineβ2
MG abnormal rate. But only LDT therapy was related to eGFR value (t=2.33,
p=0.0204) (Table 4).Age(OR=1.02,95%CI=1.00-1.05,p=0.0478)
was related to both urine β2 MG abnormal rate (Table
3) and eGFR value (t=-4.88, p<0.0001) (Table4).Influence
factors included in this study did not show obvious correlation to other renal
tubular index, such as serum calcium and serum phosphorus level.
3.4. Clinical Course of Patients Who Developed Renal Tubular Dysfunction During Long-Term NAs Antiviral Therapy
In this study 135/255(52.94%) patients with CHB developed renal tubular injury and 37 of them (27.40%) were accompanied with mild to moderate eGFR value decrease during long-time antiviral therapy. Only one of all these patients was diagnosed as Fanconi syndrome who with hypophosphatemia and clinical manifestation including fatigue and low limbs ache.117 of the 135 CHB patients finished the 52-weeks’ follow-up and were included into the last data analysis. 59 of these patients continued ADV-including antiviral therapy for another 52 weeks (25 mono therapy and 34 ADV plus LAM or ETV or LDT), and the other 58 patients continued any ADV-excluding NAs antiviral therapy or ceasing antiviral therapy.
As
showed in (Table 5), patients in the two antiviral therapy groups had good
comparability in the gender, age and liver hardness proportion. Compared to the
baseline, urine β2 MG level of patients in ADV-excluding group decreased at
average of 3.94mg/L per year, and eGFR value increased at average of
1.7mL/minute per year. On the contrary, urine β2
MG level and eGFR value of patents in ADV-including group both deteriorated
compared to the baseline (Table 5).
Unfortunately, we found that although the renal tubular function indexes of these CHB patients in ADV-excluding group improved markedly compared to the baseline, but at the end of 52-weeks’ follow-up the urine β2MG level recovered completely in only 11.36% patients.In this study we found that the renal function of most patients who developed renal injury during long-term anti-HBV therapy could not recover completely during the 52-weeks’ ADV-excluding therapy, and especially in those patients who developed both renal tubular function indexes abnormal and eGFR value decrease.
4. Discussion
NAs had become first-line anti-HBV drugs in clinical practice by possessing the advantages of convenient, efficient and well tolerated [26,28-30]. However, because of the rare HBV eradication and high recurrence rate after drug withdrawal, the majority of CHB patients will require long-time antiviral treatment even the lifetime [26,28]. Therefore, the Adverse Drug Reactions Monitoring (ADRM) of these drugs, especially the effect on renal function, are of paramount importance for ensuring long term usage. Drugs such as ADV tend to be more harmful to the tubular than to the glomerular cells, and in this case the decrease in GFR value develops presumably secondarily after tubular injury, being thereby a relatively late event [31] Serum and urine Low-Molecular-Weight Proteins (LMWP) level, such as β2 MG exhibit renal handling compatibility to that of an “ideal” marker of GFR. Hence, determining the serum concentrations of various LMWPs has been proposed as a useful approach to evaluate GFR impairment [32-36]. This is a study, which evaluated both GFR values estimated with CKD–EPI equation and serum or urine LMWP level. 52.94% CHB patients developed urine β2 MG increase during long-term NAs therapy but in these patients the abnormal rate of eGFR value was only 27.40%. The results suggested that urine LMWP level such as β2 MG level was the more sensitive indicator for evaluation of NAs induced renal tubular dysfunction in patients with CHB. Recently Takagi J’s report got the same result [37].In this study we found not only patients who received long-term NAs antiviral therapy, but also those untreated disease controls showed high urine β2 MG abnormal rate. It indicated that there were subclinical renal dysfunctions in most CHB patients even before NAs therapy. Previous reports also indicated that renal injury was common in patients with CHB because of immune complex glomerulopathy and HBV direct renal injury [38-41]. Unfortunately, in this study we did not obtain the baseline urine β2 MG data of patients with long-term antiviral therapy. Thus, in our study the exact impact of the hepatic disease on renal function and the specific tubular toxicity of NAs cannot be reliably appreciated.
In addition, in this study we found after
adjusting influence of age and treatment duration only urine β2MG
abnormal rate in ADV therapy group was significantly higher than that in LDT
long-term therapy group. And an increase of more than 10×UNL of urine β2 MG
was only detected in the ADV mono or combine therapy group (Table 2). These
results suggested that antivirals may be one of the risk factors for renal
injury during long-term NAs therapy. When investigating
potential factors associated with urine β2
MG abnormal and eGFR decrease we identified age as the risk factor for both
eGFR decrease and urine β2 MG increase and ADV was the only uniqueone drug
which was related to the urine β2
MG abnormal during therapy. We also found that LDT had a protect effect on eGFR
value and urine β2 MG, which is also in line with the previous study [42-44].
Although we found patients in ADV mono-therapy group having high risk of urineβ2MG
abnormal, we observed ADV combined therapy did not increase the risk of renal
injury compared to ADV monotherapy. The result was in line with previous study [44].
Unfortunately,
in our study we observed the majority of those patients with CHB who developed
renal injury during long-term antiviral therapy can’t completely recover after
adjusting antiviral to ADV-excluding treatment at the end of the 52-weeks’
follow-up. The result was not consistent with the registration study [14,19].
The possible reason was first, most patients in our study had received longer
time treatment than those in the registration study and the majority of them in
clinical practice have to continue receiving NAs
treatment instead of drug withdrawal; second, the kidney injury of these
patients was ignored because of low sensitivity of eGFR, and then delayed the
drug adjusting time in practice; third, the prolonged NAs treatment may cause
renal interstitial fibrosis. When investigating the potential factors
associated with renal function improvement, we found that the renal function
level before therapy adjustment was the unique significant factor. The result
suggested that early detection of injury determined the improvement degree of
renal function.
The limitation of this study is the small size and the short time of the prospective observation follow up. As a result, clinical trials with large sample size and long-term follow-up are needed to confirm and investigate the optimal therapy for patients with obvious tubular damage, especially for patients with history of drug resistance mutation and need long-time antiviral therapy.
5. Conclusion
In summary, the results of this clinical study suggest
that many patients developed renal injury during prolonged ADV-including
anti-HBV therapy and urinary β2 MG are more sensitive to monitor NAs antiviral therapy induced relatedrenal
tubular injury. Prolonged ADV-including antiviral therapy maybe causes irreversible
renal tubular damage in CHB patients.
6. Acknowledgement
We thank all patients for their understanding and
participation.
Characteristics |
Patient Groups |
Diseases control |
P value |
||||
ADV |
LDT |
LAM |
ETV |
NAscombine therapy |
|||
number |
83 |
27 |
27 |
39 |
79 |
25 |
/ |
Age, (Md, Q1~Q3) |
44(40~51) |
36(30~44) |
50(37~59) |
39(34~47) |
41(36~50) |
41(34~46) |
0.0038 |
Male sex |
66 |
22 |
17 |
34 |
69 |
19 |
0.097 |
Duration of therapy, months (Md, Q1~Q3) |
36(24~72) |
18(12~24) |
48(24~72) |
24(17~42) |
36(24~60) |
0(0~0) |
<0.0001 |
Scr level before antivial therapy(μmol/L) (X ± SD) |
68.68 ±11.34 |
63.43±10.43 |
65.20±9.03 |
70.62 ±15.54 |
67.09±12.51 |
/ |
0.1888 |
eGFR before antivial therapy(mL/minute) (X ± SD) |
114.27 ±19.05 |
129.46±26.01 |
114.27 ±28.38 |
116.12 ±24.14 |
119.58 ±22.83 |
/ |
0.0660 |
Liver hardness(Kpa) |
10(9~15) |
10(10~14) |
12(10~15) |
10(10~14) |
10(10~14) |
9 (7–19) |
0.442 |
ALT(IU/ml) |
25.87±10.27 |
23.5±9.59 |
27.58±16.48 |
25.52±24.55 |
28.97±17.53 |
479.08±150.41 |
0.001 |
AST(IU/ml) |
25.65±6.42 |
27.14±7.59 |
26.75±8.87 |
23.83±7.41 |
26.123±8.23 |
312.36±99.41 |
0.001 |
TBI(umol/L) |
15.69±6.00 |
18.68±8.56 |
17.23±7.48 |
17.28±8.96 |
13.48±5.40 |
76.09±25.10. |
0.001 |
ALB(g/ml) |
45.59±2.84 |
45.96±2.26 |
44.82±2.91 |
45.83±2.16 |
45.70±2.95 |
36.76±5.99 |
0.001 |
HBVDNA (Log IU/ml) (X ± SD) |
2.44±0.32 |
2.75±1.05 |
2.50±0.50 |
2.44±0.72 |
2.44±0.71 |
6.83(2.00~7.70) |
0.001 |
Md: median;lamivudine(LAM), adefovir dipivoxil (ADV), telbivudine(LDT), entecavir(ETV); NAs combine therapy including LAM or LDT or ETV plus ADV; Scr: Serum creatinine;eGFR: estimated Glomerular Filtration Rate |
Table 1: Demographic and clinical data of all patients accepting long-term nucleos(t)ide analogue antiviral therapy.
Characteristics |
Patient groups |
|
||||||
|
||||||||
ADV |
LDT |
LAM |
ETV |
NAs combine therapy |
Unexposed |
P value |
||
Urinary β2 MG(mg/L) (Md, Q1~Q3) |
0.655(0.22~2.1) |
0.15(0.10~0.25) |
0.345(0.21~0.46) |
0.285(0.125~0.65) |
0.35(0.12~0.83) |
0.64(0.15~1.02) |
0.163 |
|
Urinary β2MG abnormal rate(%) |
Urinary β2 MG ≥ 10×UNL |
10/58(17.24%) |
0/4(0.00%) |
0/15(0.00%) |
0/18(0.00%) |
8/39 (20.51%) |
0/15(0.00%) |
<0.001 |
10×UNL>urinary β2MG≥5×UNL |
18/58(31.03%) |
0/4(0.00%) |
0/15(0.00%) |
2/18(11.11%) |
2/39 (5.12%) |
1/15(6.67%) |
||
5×UNL>urinary β2 MG >1×UNL |
30/58(51.72%) |
4/4(100%) |
15/15(100%) |
16/18(88.88%) |
29/39 (74.35%) |
14/15(93.33%) |
||
Serum β2 MG (mg/L) (Md, Q1~Q3) |
2.01(1.71~2.36) |
1.71(1.57~1.99) |
1.84(1.55~2.23) |
1.72(1.53~1.96) |
1.97(1.73~2.23) |
2.49 (1.87–2.83) |
<0.0001 |
|
Serum calcium(mmol/L) (Md, Q1~Q3) |
2.40(2.34~2.46) |
2.39(2.35~2.48) |
2.40(2.35~2.48) |
2.41(2.35~2.48) |
2.43(2.35~2.48) |
2.21(2.13~2.28) |
0.099 |
|
Serum phosphorus(mmol/L) (Md, Q1~Q3) |
1.01(0.93~1.09) |
1.07(1.01~1.18) |
1.05(0.88~1.16) |
0.995(0.88~1.16) |
0.995(0.88~1.16) |
1.22(1.05~1.33) |
0.219 |
|
Scr change(μmol/L) (X ± SD) |
5.51±9.89 |
3.22±7.05 |
5.04±12.34 |
2.46±11.01 |
5.12±12.29 |
/ |
0.971 |
|
eGFR change (mL/minute) (X ± SD) |
-11.47±19.49 |
-7.08±17.92 |
-10.29±27.30 |
-5.73±23.90 |
-9.43±19.45 |
/ |
0.925 |
|
Md: median;UNL: upper normal limit; LNL: lower normal limit; eGFR:estimated Glomerular Filtration Rate; Scr: Serum creatinine; Urinary β2 MG: Urine β2 Micro globulin; Serum β2 MG: Serum β2 Micro globulin |
Table 2: Renal function of patients with nucleos(t)ide antiviral therapy for more than 6 months.
Characteristics |
Coefficient B |
Standard Error |
Wald Chi-Square |
Pr > ChiSq |
OR |
||
Point estimate |
95%CI |
||||||
Lower limit |
Upper limit |
||||||
Age |
0.0233 |
0.01 |
3.92 |
0.0478 |
1.02 |
1 |
1.05 |
Treatment duration |
0.01 |
0.01 |
1.5 |
0.221 |
1.01 |
1 |
1.02 |
NAs combine therapy |
-0.05 |
0.25 |
0.04 |
0.8449 |
0.45 |
0.16 |
1.28 |
LDT |
-1.54 |
0.47 |
10.65 |
0.0011 |
0.1 |
0.03 |
0.4 |
LAM |
0.03 |
0.38 |
0.01 |
0.9282 |
0.49 |
0.14 |
1.74 |
ETV |
0.01 |
0.31 |
0 |
0.9761 |
0.48 |
0.17 |
1.41 |
ADV |
0.81 |
0.26 |
9.96 |
0.0016 |
1.07 |
0.38 |
3.04 |
ADV: adefovir dipivoxil ; LAM: lamivudine, LDT: telbivudine, ETV: entecavir |
Table3: Risk factors for urinary β2micro globulin abnormality rete in patients with CHB onnucleos(t)ide antiviral therapy.
Characteristics |
Coefficient B |
Standard Error |
t |
P |
Age |
-0.51 |
0.10 |
-4.88 |
<.0001 |
Treatment duration |
-0.02 |
0.05 |
-0.50 |
0.6161 |
NAs combine therapy |
7.16 |
4.85 |
1.48 |
0.1413 |
LDT |
12.67 |
5.43 |
2.33 |
0.0204 |
LAM |
3.74 |
5.91 |
0.63 |
0.5272 |
ETV |
3.12 |
5.06 |
0.62 |
0.5388 |
ADV |
1.20 |
4.86 |
0.25 |
0.8052 |
ADV: adefovir dipivoxil ; LAM: lamivudine, LDT: telbivudine, ETV: entecavir |
Table4: Risk factors for estimated Glomerular Filtration Rate (eGFR)inpatients with CHB on nucleos(t)ide antiviral therapy.
Group
|
Age, (Md, Q1~Q3) |
Mail Sex |
Liver hardness (Kpa) |
renal function at the begin of follow-up |
|
change of renal function indicators |
|||||||
Urinary β2 MG (mg/L) |
Serum β2 MG (mg/L) |
Serum calcium (mmol/L) |
Serum phosphorus (mmol/L) |
eGFR (mL/min) |
Urinary β2 MG (mg/L) |
Serum β2 MG (mg/L) |
Serum calcium (mmol/L) |
Serum phosphorus (mmol/L) |
eGFR (mL/min) |
||||
ADV-including |
46(39~53) |
49 |
11(10~15) |
4.29±10.20 |
2.19±0.44 |
2.42±0.09 |
1.02±0.13 |
106.52±24.73 |
-1.41±10.82 |
-0.13±0.55 |
-0.07±0.18 |
-0.13±0.55 |
-5.66±17.71 |
ADV-excluding |
44(37~56) |
47 |
12(10~15) |
4.09±9.83 |
2.27±0.701 |
2.32±0.11 |
0.96±0.155 |
96.72±18.14 |
-3.94±10.82 |
-0.24±0.77 |
-0.06±0.13 |
-0.01±0.55 |
1.70±15.81 |
P value |
0.965 |
0.776 |
0.496 |
0.698 |
0.321 |
0.322 |
0.068 |
0.317 |
0.157 |
0.423 |
0.628 |
0.528 |
0.166 |
Md: median; ADV: adefovir dipivoxil ; LAM: lamivudine, LDT: telbivudine, ETV: entecavir |
Table5:Clinical course of patients developed renal dysfunction during nucleos(t)ide long-term antiviral therapy.
1.
Trepo C, Chan HL, Lok A (2014) Hepatitis
B virus infection. Lancet 384: 2053-2063.
3.
Kwon H, Lok AS (2011)
Hepatitis B therapy. Nat Rev Gastroenterol Hepatol8: 275-284.
14.
Fontana RJ (2009) Side effects of
long-term oral antiviral therapy for hepatitis B. Hepatology 49: 185-195.
27.
WHO Guidelines Approved by the Guidelines Review
Committee. (2015) Guidelines for the
Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection.
Geneva: World Health OrganizationCopyright (c) World Health Organization.